Hologic introduces breast biopsy system, claims improved efficiency

Hologic’s new Brevera breast biopsy system with CorLumina imaging technology is now available in the U.S. Designed to allow radiologists to make accurate decisions for 2D and 3D breast biopsies, Hologic claims the system will also cut procedure times by 25 percent.

The system combines tissue acquisition, real-time imaging, sample verification and advanced post-biopsy handling in one, integrated system.

"We're proud to launch the Brevera system, a major breakthrough for radiologists who, for the first time, will be able to image and verify tissue samples in real-time in the procedure room," said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions.

Radiologists performing traditional stereotactic breast biopsies left the patient under compression while moving to another room to examine tissue samples. With Brevera, radiologists will have access to tissue samples in the procedure room “in a few seconds.” This could potentially save patients’ up to 10 minutes.

The CorLumina imaging system automates the tissue sample collection and separation process, which allows patient tissue to be sent to pathology with little to no manual handling. The system also features PACS integration for advanced image sharing and transfer of patient records.

"The Brevera system provides clinicians with more information at the point of care and women with a vastly improved experience, resulting in significant cost and time savings without compromising accuracy or patient health outcomes," said Valenti. "The system transforms the stereotactic breast biopsy procedure as we know it, and serves as further proof of Hologic's commitment to better serve the needs of our customers and their patients."

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.